Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
Z Megyesfalvi, CM Gay, H Popper… - CA: a cancer journal …, 2023 - Wiley Online Library
Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …
Small-cell lung cancer
CM Rudin, E Brambilla, C Faivre-Finn… - Nature Reviews Disease …, 2021 - nature.com
Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …
[HTML][HTML] Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
AMC Dingemans, M Früh, A Ardizzoni… - Annals of …, 2021 - annalsofoncology.org
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
JE Chaft, A Rimner, W Weder, CG Azzoli… - Nature reviews Clinical …, 2021 - nature.com
The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …
discussions of surgical resectability and medical operability determine the modality of …
Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase …
D Morgensztern, B Besse, L Greillier… - Clinical Cancer …, 2019 - AACR
Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …
first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab …
Unravelling the biology of SCLC: implications for therapy
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
Lung cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
R Rami‐Porta, H Asamura, WD Travis… - CA: a cancer journal …, 2017 - Wiley Online Library
Answer questions and earn CME/CNE The revision for the eighth edition of the tumor, node,
and metastasis (TNM) classification of lung cancer was based on analyses of the …
and metastasis (TNM) classification of lung cancer was based on analyses of the …
YAP drives fate conversion and chemoresistance of small cell lung cancer
Q Wu, J Guo, Y Liu, Q Zheng, X Li, C Wu, D Fang… - Science …, 2021 - science.org
Small cell lung cancer (SCLC) has a high degree of plasticity and is characterized by a
remarkable response to chemotherapy followed by the development of resistance. Here, we …
remarkable response to chemotherapy followed by the development of resistance. Here, we …
Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung
Cancer (SCLC) provide recommended management for patients with SCLC, including …
Cancer (SCLC) provide recommended management for patients with SCLC, including …
[HTML][HTML] Scientific advances in lung cancer 2015
AS Tsao, GV Scagliotti, PA Bunn Jr, DP Carbone… - Journal of Thoracic …, 2016 - Elsevier
Lung cancer continues to be a major global health problem; the disease is diagnosed in
more than 1.6 million new patients each year. However, significant progress is underway in …
more than 1.6 million new patients each year. However, significant progress is underway in …